Suppr超能文献

B细胞前体急性淋巴细胞白血病在NOD-SCID小鼠中的良好植入。

Good engraftment of B-cell precursor ALL in NOD-SCID mice.

作者信息

Baersch G, Möllers T, Hötte A, Dockhorn-Dworniczak B, Rübe C, Ritter J, Jürgens H, Vormoor J

机构信息

Klinik und Poliklinik für Kinderheilkunde, Westfälische Wilhelms-Universität Münster.

出版信息

Klin Padiatr. 1997 Jul-Aug;209(4):178-85. doi: 10.1055/s-2008-1043947.

Abstract

BACKGROUND

In vivo models for human B cell precursor ALL have been established by transplanting human leukemic cells onto immune-deficient SCID mice. High risk and relapsed leukemias engraft very well in these mice, however, good prognosis pediatric ALL often grow poorly if at all. Recently a new, even more immune-deficient mouse strain has been bred by crossing the scid mutation onto the NOD mouse background. As these NOD-SCID mice have been shown to be better recipients for human myeloid cells the goal of this study was to test these mice as hosts for human acute lymphoblastic leukemia cells.

PATIENTS AND METHODS

Bone marrow or peripheral blood cells from/pediatric and one adult patient with B-cell precursor ALL were transplanted onto immune-deficient NOD-SCID mice according to established protocols.

MAIN RESULTS

ALL cells from 6 out of the 8 patients (75%) successfully engrafted the NOD-SCID mice and from 4 patients (50%) led to an extensive leukemic infiltration in the murine marrow (> 10%). High level human cell engraftment could be demonstrated by flow cytometry, Southern blot analysis and cytology. By cytology and immunophenotype the leukemia in the mice was indistinguishable from the original leukemia in the patients. The presence of few human eosinophils in the marrow of highly engrafted mice indicates minimal coengraftment of residual normal cells. Development of overt leukemia in the mice after transplantation of cells from different patients varied between 1.5 and 7 months. Interestingly and in contrast to myeloid cells, conditioning of the mice by sublethal irradiation was not necessary for successful engraftment. Limiting dilution experiments with leukemic blasts from one patient showed that as few as 10000 cells were sufficient to transfer the leukemia onto NOD-SCID mice.

CONCLUSIONS

NOD-SCID mice are sensitive recipients for human ALL xenografts.

摘要

背景

通过将人白血病细胞移植到免疫缺陷的SCID小鼠上,已建立了人B细胞前体急性淋巴细胞白血病(ALL)的体内模型。高危和复发白血病在这些小鼠中移植效果很好,然而,预后良好的儿童ALL在这些小鼠中往往生长不良,甚至根本不生长。最近,通过将scid突变与NOD小鼠背景杂交,培育出了一种新的、免疫缺陷程度更高的小鼠品系。由于这些NOD-SCID小鼠已被证明是人类髓细胞的更好受体,本研究的目的是测试这些小鼠作为人类急性淋巴细胞白血病细胞宿主的情况。

患者和方法

根据既定方案,将来自8例儿科和1例成人B细胞前体ALL患者的骨髓或外周血细胞移植到免疫缺陷的NOD-SCID小鼠上。

主要结果

8例患者中有6例(75%)的ALL细胞成功移植到NOD-SCID小鼠体内,4例患者(50%)导致小鼠骨髓广泛白血病浸润(>10%)。通过流式细胞术、Southern印迹分析和细胞学可证明高水平的人细胞移植。通过细胞学和免疫表型分析,小鼠中的白血病与患者原来的白血病无法区分。在高度移植的小鼠骨髓中存在少量人嗜酸性粒细胞,表明残留正常细胞的共移植极少。移植来自不同患者的细胞后,小鼠明显白血病的发生时间在1.5至7个月之间。有趣的是,与髓细胞相反,亚致死剂量照射对小鼠进行预处理对于成功移植并非必要。对1例患者的白血病母细胞进行的有限稀释实验表明,仅10000个细胞就足以将白血病转移到NOD-SCID小鼠上。

结论

NOD-SCID小鼠是人类ALL异种移植的敏感受体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验